Kirk R Gustafson

This inventor holds 27 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents, primarily in Antiviral Compounds. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The United States of America as Represented by the Department of Health, The United States of America as Represented by the Secretary of. Active years: 1997-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kirk R Gustafson. Retrieved from https://idiyas.com/inventor/kirk-r-gustafson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 1)

% Patents Active = 81.5

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 66(Granted Patents)

Location History:

Mt. Airy, MD (US) (1997 - 2004)
Frederick, MD (US) (1998 - 2019)

Company Filing History:

17 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

5 out of 1,217

The United States of America as Represented by the Department of Health

patents

2 out of 2,202

The United States of America as Represented by the Secretary of

patents

4. 2 out of 2,430

University of Illinois

patents

5. 2 out of 16,278

USA as Represented by Secretary of the Navy

patents

6. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2019

Loading Chart...

Areas of Expertise:

Antiviral Compounds

Macrolides

HIF-1 Inhibitors

V-ATPase Inhibitors

Nuclear Factor Kappa B

Chondropsin

Cancer Treatment

Antiretroviral

Biologically Active

Antiviral Proteins

Cytotoxic Effects

Cyanovirin

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10246463 - Hypoxia-inducible factor 1 (HIF-1) inhibitors (2019-04-02),

2. 9820965 - Biologically active macrolides, compositions, and uses thereof (2017-11-21),

3. 9314448 - Method of inhibiting ABCG2 and other treatment methods (2016-04-19),

4. 9238069 - Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment (2016-01-19),

5. 9139595 - Biologically active macrolides, compositions, and uses thereof (2015-09-22),

6. 8741947 - Biologically active macrolides, compositions, and uses thereof (2014-06-03),

7. 8729053 - Nuclear factor kappa B pathway inhibitor composition and use of same (2014-05-20),

8. 8609716 - Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof (2013-12-17),

9. 8470888 - Botryllamides and method of inhibiting PGP in a mammal afflicted with cancer (2013-06-25),

10. 8278348 - Chondropsin-class antitumor V-atpase inhibitor compounds, compositions and methods of use thereof (2012-10-02),

11. 7790764 - Biologically active macrolides, compositions, and uses thereof (2010-09-07),

12. 7521475 - Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof (2009-04-21),

13. 7205334 - Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof (2007-04-17),

14. 7144918 - Biologically active macrolides, compositions, and uses thereof (2006-12-05),

15. 6987096 - Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof (2006-01-17),

Title: Innovations by Kirk R. Gustafson in Patent Developments

Introduction

Kirk R. Gustafson, based in Frederick, MD, is an influential inventor known for his contributions to the field of biochemistry and medicinal chemistry. With a remarkable portfolio of 27 patents, he continues to push the boundaries of innovation through his research and development of novel compounds and pharmaceutical compositions.

Latest Patents

Gustafson's latest patents showcase his expertise in creating small molecule inhibitors of hypoxia-inducible factor 1 (HIF-1). These innovative compounds are designed to suppress HIF-1 activity by inhibiting the interaction between the HIF-1 alpha subunit and the transcriptional co-activator protein p300. Furthermore, his work also involves biologically active macrolides and their compositions, which provide methods for treating conditions by inhibiting vacuolar-type (H+)-ATPase and targeting cancer therapies.

Career Highlights

Throughout his career, Kirk R. Gustafson has held significant positions at prestigious organizations, including the United States Department of Health and Human Services and the United States Department of Health. His role in these institutions highlights his commitment to advancing health-related innovations that have the potential to benefit public health.

Collaborations

Gustafson has collaborated with esteemed professionals such as Michael R. Boyd and James Brislin McMahon. These partnerships have led to the development of groundbreaking research and reinforcing his contributions to the field of health sciences.

Conclusion

Kirk R. Gustafson exemplifies the spirit of innovation in the realm of pharmaceutical developments. With an extensive number of patents and impactful collaborations, he continues to be a key figure in advancing therapeutic solutions, demonstrating the importance of inventive minds in the scientific community.

Profile summary based on public USPTO records.